Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors
    17.
    发明申请
    Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors 审中-公开
    对苯二甲酸酯化合物和组合物及其作为HIV整合酶抑制剂的用途

    公开(公告)号:US20100016379A1

    公开(公告)日:2010-01-21

    申请号:US12300171

    申请日:2007-04-18

    摘要: Described herein are compounds having a terephthalamate structural feature. Also described herein, are methods of making such compounds, methods of using such compounds to modulate the activity of HIV integase, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology of AIDS or infection with HIV.

    摘要翻译: 本文描述的是具有对苯二甲酸酯结构特征的化合物。 本文还描述了制备这种化合物的方法,使用这些化合物调节HIV整合酶的活性的方法,以及包含这些化合物的药物组合物和药物。 本文还描述了使用这些化合物,药物组合物和药物来治疗和/或预防和/或抑制和/或改善AIDS或HIV感染的病理学和/或症状的方法。

    Compounds and compositions as protein kinase inhbitors
    18.
    发明授权
    Compounds and compositions as protein kinase inhbitors 失效
    化合物和组合物作为蛋白激酶抑制剂

    公开(公告)号:US07846923B2

    公开(公告)日:2010-12-07

    申请号:US12299687

    申请日:2007-05-11

    IPC分类号: C07D471/00 A61K31/54

    CPC分类号: C07D471/14

    摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

    摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,Bcr-Abl异常活化的疾病或病症 ,Bcr-Abl(T315I),ALK,BLK,BMX,BRK,C-kit,c-RAF,CSK,c-SRC,EGFR,Fes,FGFR3,Flt3,Fms,Fyn,IGF-1R,IR,JAK( 2),JAK(3),KDR,Lck,NLK,p70S6K,PDGFRα,Ros,SAPK2α,SGK,SIK,Syk,Tie2和TrkB激酶。

    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS
    20.
    发明申请
    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS 失效
    作为蛋白激酶抑制剂的化合物和组合物

    公开(公告)号:US20100048552A1

    公开(公告)日:2010-02-25

    申请号:US12299687

    申请日:2007-05-11

    CPC分类号: C07D471/14

    摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

    摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,Bcr-Abl异常活化的疾病或病症 ,Bcr-Abl(T315I),ALK,BLK,BMX,BRK,C-kit,c-RAF,CSK,c-SRC,EGFR,Fes,FGFR3,Flt3,Fms,Fyn,IGF-1R,IR,JAK( 2),JAK(3),KDR,Lck,NLK,p70S6K,PDGFRα,Ros,SAPK2α,SGK,SIK,Syk,Tie2和TrkB激酶。